AKTOCYTE: A Revolutionary Nutraceutical for Cancer Care
Recently, in a groundbreaking collaboration, scientists from the Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd., Bengaluru, have developed AKTOCYTE tablets, aiming to enhance the quality of life for cancer patients undergoing radiotherapy.
Key Points
- Remarkable Recovery in Pelvic Cancer Patients: AKTOCYTE tablets demonstrate exceptional efficacy in pelvic cancer patients undergoing radiotherapy, leading to significant recovery and eliminating the need for surgical interventions.
- Versatile Applications: Positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, AKTOCYTE showcases versatility in addressing various aspects of cancer care.
- Regulatory Approval: AKTOCYTE received approval from the Food Safety ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 Brain-Computer Interface to Restore Natural Speech
- 2 Neuralink to Implant 'Blindsight' Chip in First Human by 2025
- 3 Unexpected Atmospheric Gas on Exoplanet K2-18b
- 4 India Signs Deal with France for 26 Rafale-Marine Fighter Jets
- 5 SpaceX Launches Historic Fram2 Mission
- 6 Indian Army Inducts Indigenous FPV Drones
- 7 India’s First Prototype Fast Breeder Reactor Set for Commissioning in 2025
- 8 Blood Test for Cervical Cancer Monitoring
- 9 Google Launches Ironwood: 7th-Generation TPU for AI Workloads
- 10 QpiAI-Indus Quantum Computer